Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: Metabolic changes that unravel novel drug targets

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 4, 2004, Pages 611-623

  Yoon, Sang Sun ^a   Hassett, Daniel J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Alginate production; Anaerobic metabolism; Biofilms; Cystic fibrosis; Mucociliary clearance; Pseudomonas aeruginosa; Quorum sensing

Indexed keywords

ALGINIC ACID; CIPROFLOXACIN; CURCUMIN; FLAGELLIN; HYDROGEN PEROXIDE; PIPERACILLIN; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BIOFILM; CYSTIC FIBROSIS; DRUG TARGETING; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSCRIPTION; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; MOLECULAR MECHANICS; MOLECULAR WEIGHT; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 4444288670     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.4.611     Document Type: Review

References (116)

1. Ratjen F, Doring G. Cystic fibrosis. Lancet 361, 681-689 (2003).
2. Meyer KC, Zimmerman J. Neutrophil mediators, pseudomonas, and pulmonary dysfunction in cystic fibrosis. J. Lab. Clin. Med. 121, 654-661 (1993).
3. Jagger KS, Robinson DL, Franz MN, Warren RL. Detection by enzyme-linked immunosorbent assays of antibody specific for pseudomonas proteases and exotoxin A in sera from cystic fibrosis patients. J. Clin. Microbiol. 15, 1054-1058(1982).
4. Su W, Porter S, Kustu S, Echols H. DNA-looping and enhancer activity - association between DNA-bound Ntrc activator and RNA polymerase at the bacterial Glna promoter. Proc. Natl Acad. Sci. USA 87, 5504-5508(1990).
5. Erwin AL, VanDevanter DR. The Pseudomonas aeruginosa genome: how do we use it to develop strategies for the treatment of patients with cystic fibrosis and pseudomonas infections? Curr. Opin. Pulm. Med. 8, 547-551(2002).
6. Stotland PK, Radzioch D, Stevenson MM. Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis. Pediatr. Pulmonol. 30, 413-424(2000).
7. Tarran R, Grubb BR, Parsons D et al. The CF salt controversy: in vivo observations and therapeutic approaches. Mol. Cell 8, 149-158 (2001).
8. Vasil ML. Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology. J. Pediatr. 108, 800-805 (1986).
9. Botzenhart K, Doring G. Ecology and epidermology of Pseudomonas aeruginosa. In: Pseudomonas aeruginosa as an Opportunistic Pathogen. Campa M, Bendinelli M, Friedman H (Eds), Plenum Press, NY, USA (1993).
10. Greenberg EP. Bacterial genomics. Pump up the versatility. Nature 406, 947-948 (2000).
11. Bayley SA, Morris DW, Broda P. The relationship of degradative and resistance plasmids of Pseudomonas belonging to the same incompatibility group. Nature 280, 338-339 (1979).
12. Ingram JM, Hassan HM. The resistance of Pseudomonas aeruginosa to chloramphenicol. Can. J. Microbiol. 21, 1185-1191 (1975).
13. Knothe H, Krcmery V. Apparent antagonism by a resident R plasmid for entry of related gentamicin-tobramycin resistance plasmids in Pseudomonas aeruginosa. Chemotherapy 21, 281-283(1975).
14. Olsen RH, Hansen J. Evolution and utility of a Pseudomonas aeruginosa drug resistance factor. J. Bacteriol. 125, 837-844 (1976).
15. Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406, 959-964 (2000).
16. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292, 107-113 (2002).
17. de Kievit TR, Iglewski BH. Bacterial quorum sensing in pathogenic relationships. Infect. Immun. 68, 4839-4849 (2000).
18. Parsek MR, Greenberg EP. Quorum sensing signals in development of Pseudomonas aeruginosa biofilms. Methods Enzymol. 310, 43-55 (1999).
19. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407, 762-764 (2000).
20. Hassett DJ, Cuppoletti J, Trapnell B et al. Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv. Drug Deliv. Rev. 54, 1425-1443 (2002).
21. Costerton JW. Introduction to biofilm. Int. J. Antimicrob. Agents. 11, 217-221 (1999).
22. O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30, 295-304 (1998).
23. Wolfaardt GM, Lawrence JR, Robarts RD, Caldwell DE. The role of interactions, sessile growth and nutrient amendments on the degradative efficiency of a microbial consortium. Can. J. Microbiol. 40, 331-340 (1994).
24. Boyd A, Chakrabarty AM. Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. J. Ind. Microbiol. 15, 162-168 (1995).
25. Davey ME, Caiazza NC, O'Toole GA. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PA01. J. Bacteriol. 185, 1027-1036 (2003).
26. Hentzer M, Teitzel GM, Balzer GJ et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol. 183, 5395-5401 (2001).
27. Hassett DJ, Ma J-F, Elkins JG et al. Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol. Microbiol. 34, 1082-1093 (1999).
28. Anwar H, Dasgupta M, Lam Y, Costerton JW. Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. J. Antimicrob. Chemother. 24, 647-655 (1989).
29. Coquet L, Junter GA, Jouenne T. Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin. J. Antimicrob. Chemother. 42, 755-760 (1998).
30. Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob. Agents Chemother. 27, 619-624 (1985).
31. Evans DJ, Allison DG, Brown MP, Gilbert P. Susceptibility of Pseudomonas aeruginosa and Escherichia coli biofilms towards ciprofloxacin: effect of specific growth rate. J. Antimicrob. Chemother. 27, 177-184 (1991).
32. Teitzel GM, Parsek MR. Heavy metal resistance of biofilm and planktonic Pseudomonas aeruginosa. Appl. Environ. Microbiol. 69, 2313-2320 (2003).
33. Suci PA, Mittelman MW, Yu FP, Geesey GG. Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 38, 2125-2133 (1994).
34. Tanaka K, Takahashi H. Cloning, analysis and expression of an rpoS homolog gene from Pseudomonas aeruginosa PAO1. Gene 150, 81-85 (1994).
35. Xu KD, Franklin MJ, Park CH, McFeters GA, Stewart PS. Gene expression and protein levels of the stationary phase sigma factor, RpoS, in continuously-fed Pseudomonas aeruginosa biofilms. FEMS Microbiol. Lett. 199, 67-71 (200 1).
36. Heydorn A, Ersboll B, Kato J et al. Statistical analysis of Pseudomonas aeruginosa biofilm development: impact of mutations in genes involved in twitching motility, cell-to-cell signaling, and stationary-phase σ-factor expression. Appl. Environ. Microbiol. 68, 2008-2017 (2002).
37. Whiteley M, Bangera MG, Bumgarner RE et al. Gene expression in Pseudomonas aeruginosa biofilms. Nature 413, 860-864 (2001).
38. Sub SJ, Silo-Suh L, Woods DE et al. Effect of rpoS mutation on the stress response and expression of virulence factors in Pseudomonas aeruginosa. J. Bacteriol. 181, 3890-3897 (1999).
39. Rashid MH, Rumbaugh K, Passador L et al. Polyphosphate kinase is essential for biofilm development, quorum sensing, and virulence of Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 97, 9636-9641 (2000).
40. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280, 295-298 (1998).
41. O'Toole GA, Gibbs KA, Hager PW, Phibbs PV Jr, Kolter R. The global carbon metabolism regulator Crc is a component of a signal transduction pathway required for biofilm development by Pseudomonas aeruginosa. J. Bacteriol. 182, 425-31 (2000).
42. Parkins MD, Ceri H, Storey DG. Pseudomonas aeruginosa GacA, a factor in multihost virulence, is also essential for biofilm formation. Mol. Microbiol. 40, 1215-1226 (2001).
43. Finelli A, Gallant CV, Jarvi K, Burrows LL. Use of in-biofilm expression technology to identify genes involved in Pseudomonas aeruginosa biofilm development. J. Bacteriol. 185, 2700-2710 (2003).
44. Mah TF, Pitts B, Pellock B et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426, 306-310 (2003).
45. Xu KD, Stewart PS, Xia F, Huang CT, McFeters GA. Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability. Appl. Environ. Microbiol. 64, 4035-4039 (1998).
46. Worlitzsch D, Tarran R, Ulrich M et al. Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa cystic fibrosis airway infection. J. Clin. Invest. 109, 317-325(2002).
47. Yoon SS, Hennigan RF, Hilliard GM et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev. Cell 3, 593-603 (2002).
48. Rumbaugh KP, Griswold JA, Hamood AN. The role of quorum sensing in the in vivo virulence of Pseudomonas aeruginosa. Microbes Infect. 2, 1721-1731 (2000).
49. Smith RS, Iglewski BH. Pseudomonas aeruginosa quorum-sensing systems and virulence. Curr. Opin. Microbiol. 6, 56-60 (2003).
50. Nealson KH, Platt T, Hastings JW. Cellular control of the synthesis and activity of the bacterial luminescent system. J. Bacteriol. 104, 313-322 (1970).
51. Gambello MJ, Iglewski BH. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transciptional activator of elastase expression. J. Bacteriol. 173, 3000-3009 (1991).
52. Ochsner UA, Fiechter A, Reiser J. Isolation, characterization, and expression in Escherichia coli of the Pseudomonas aeruginosa rhlAB genes encoding a rhamnosyltransferase involved in rhamnolipid biosurfactant synthesis. J. Biol. Chem. 269, 19787-19795 (1994).
53. Storey DG, Ujack EE, Rabin HR, Mitchell I. Pseudomonas aeruginosa lasR transcription correlates with the transcription of lasA, lasB, and toxA in chronic lung infections associated with cystic fibrosis. Infect. Immun. 66, 2521-2528(1998).
54. Jones S, Yu B, Bainton A et al. The lux autoinducer regulates the production of exoenzyme virulence determinants in Erwinia carotovora and Pseudomonas aeruginosa. Embo. J. 12, 2477-2482 (1993).
55. Howe TR, Iglewski BH. Isolation and characterization of alkaline protease-deficient mutants of Pseudomonas aeruginosa in vitro and in a mouse eye model. Infect. Immun. 43, 1058-1063 (1984).
56. Ochsner UA, Reiser J. Autoinducer-mediated regulation of rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA 92, 6424-6428 (1995).
57. Pearson JP, Pesci EC, Igkewski BH. Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. J. Bacteriol. 179, 5756-5767 (1997).
58. Rumbaugh KP, Griswold JA, Iglewski BH, Hamood AN. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect. Immun. 67, 5854-5862 (1999).
59. Tang HB, DiMango E, Bryan R et al. Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Infect. Immun. 64, 37-43(1996).
60. Smith RS, Fedyk ER, Springer TA, Mukaida N, Iglewski BH, Phipps RP. IL-8 production in human lung fibroblasts and epithelial cells activated by the pseudomonas autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF-κB and activator protein-2. J. Immunol. 167, 366-374 (2001).
61. Erickson DL, Endersby R, Kirkham A et al. Pseudomonas aeruginosa quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. Infect. Immun. 70, 1783-1790 (2002).
62. Middleton B, Rodgers HC, Camara M, Knox AJ, Williams P, Hardman A. Direct detection of N-acylhomoserine lactones in cystic fibrosis sputum. FEMS Microbiol. Lett. 207, 1-7 (2002).
63. Whiteley M, Lee KM, Greenberg EP. Identification of genes controlled by quorum sensing in Pseudomonas aeruginosa. Proc. Natl Acad. Sci. 96, 13904-13909 (1999).
64. Schuster M, Lostroh CP, Ogi T, Greenberg EP. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J Bacteriol. 185, 2066-2079 (2003).
65. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J. Bacteriol. 185, 2080-2095 (2003).
66. Evans LR, Linker A. Production and characterization of the slime polysaccharide of Pseudomonas aeruginosa. J. Bacteriol. 116, 915-924 (1973).
67. Chitnis CE, Ohman DE. Cloning of Pseudomonas aeruginosa algG, which controls alginate structure. J. Bacteriol. 172, 2894-2900 (1990).
68. Garrett ES, Perlegas D, Wozniak DJ. Negative control of flagellum synthesis in Pseudomonas aeruginosa is modulated by the alternative sigma factor AlgT (AlgU). J. Bacteriol. 181, 7401-7404 (1999).
69. Hassett DJ. Anaerobic production of alginate by Pseudomonas aeruginosa: alginate restricts diffusion of oxygen. J. Bacteriol. 178, 7322-7325 (1996).
70. Wyckoff TJ, Thomas B, Hassett DJ, Wozniak DJ. Static growth of mucoid Pseudomonas aeruginosa selects for nonmucoid variants that have acquired flagellum-dependent motility. Microbiology 148, 3423-3430(2002).
71. Martin DW, Schurr MJ, Mudd MH, Deretic V. Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc. Natl Acad. Sci. USA 90, 8377-8381 (1993).
72. Mathee K, Ciofu O, Sternberg C et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145, 1349-1357 (1999).
73. Bayer AS, Park S, Ramos MC, Nast CC, Eftekhar F, Schiller NL. Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa. Infect. Immun. 60, 3979-3985(1992).
74. Cabral DA, Loh BA, Speert DP. Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages. Pediatr. Res. 22, 429-431 (1987).
75. Eftekhar F, Speert DP. Alginase treatment of mucoid Pseudomonas aeruginosa enhances phagocytosis by human monocyte-derived macrophages. Infect. Immun. 56, 2788-2793 (1988).
76. Krieg DP, Bass JA, Mattingly SJ. Phosphorylcholine stimulates capsule formation of phosphate-limited mucoid Pseudomonas aeruginosa. Infec. Immun. 56, 864-873 (1988).
77. Meshulam T, Obedeanu N, Merzbach D, Sobel JD. Phagocytosis of mucoid and nonmucoid strains of Pseudomonas aeruginosa. Clin. Immunol. Immunopathol. 32, 151-165 (1984).
78. Oliver AM, Weir DM. Inhibition of bacterial binding to mouse macrophages by Pseudomonas alginate. J. Clin. Lab. Immunol. 10, 221-224 (1983).
79. Simpson JA, Smith SE, Dean RT. Alginate inhibition of the uptake of Pseudomonas aeruginosa by macrophages. J. Gen. Microbiol. 134, 29-36 (1988).
80. Hazlett LD, Rudner XL. Investigations on the role of flagella in adhesion of Pseudomonas aeruginosa to mouse and human corneal epithelial proteins. Ophthalmic Res. 26, 375-379 (1994).
81. Lillehoj EP, Kim BT, Kim KC. Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L751-L756 (2002).
82. Mahenthiralingam E, Speert DP. Nonopsonic phagocytosis of Pseudomonas aeruginosa by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. Infect. Immun. 63, 4519-4523 (1995).
83. Sanjar S. Measurement and pharmacology of mucociliary clearance. Agents Actions 34(Suppl.), 457-470 (1991).
84. Armengot M, Escribano A, Carda C, et al. Nasal mucociliary transport and ciliary ultrastructure in cystic fibrosis. A comparative study with healthy volunteers. Int. J. Pediatr. Otorhinolaryngol. 40, 27-34 (1997).
85. Cowley EA, Wang CG, Gosselin D, Radzioch D, Eidelman DH. Mucociliary clearance in cystic fibrosis knockout mice infected with Pseudomonas aeruginosa. Eur. Respir. J. 10, 2312-2318 (1997).
86. Regnis JA, Robinson M, Bailey DL et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med. 150, 66-71 (1994).
87. Doring G, Worlitzsch D. Inflammation in cystic fibrosis and its management. Paediatr. Respir. Rev. 1, 101-106 (2000).
88. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc. Natl Acad. Sci. USA 92, 3019-3023 (1995).
89. Pier GB, Grout M, Zaidi TS et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271, 64-67 (1996).
90. Schroeder TH, Lee MM, Yacono PW et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-κB translocation. Proc. Natl Acad. Sci. USA 99, 6907-6912 (2002).
91. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J. Clin. Invest. 103, 303-307 (1999).
92. Farinas J, Kneen M, Moore M, Verkman AS. Plasma membrane water permeability of cultured cells and epithelia measured by light microscopy with spatial filtering. J. Gen. Physiol. 110, 283-296 (1997).
93. Matsui H, Grubb BR, Tarran R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005-1015 (1998).
94. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85, 229-236 (1996).
95. Zabner J, Smith JJ, Karp PH, Widdicombe JH, Welsh MJ. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol. Cell 2, 397-403 (1998).
96. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Ann. Rev. Immunol. 11, 105-128 (1993).
97. Martin E, Ganz T, Lehrer RI. Defensins and other endogenous peptide antibiotics of vertebrates. J. Leukoc. Biol. 58, 128-36 (1995).
98. Cole AM, Dewan P, Ganz T. Innate antimicrobial activity of nasal secretions. Infect. Immun. 67, 3267-3275 (1999).
99. - transport in cultured cystic fibrosis airway epithelium. Am. J. Physiol. 256, C1045-C1053 (1989).
100. - analysis with solid-state electrodes. J. Gen. Physiol. 119, 3-14 (2002).
101. Grubb BR, Chadburn JL, Boucher RC. In vivo microdialysis for determination of nasal liquid ion composition. Am. J. Physiol. Cell. Physiol. 282, C1423-C1431 (2002).
102. Wasser IM, de Vries S, Moenne-Loccoz P, Schroder I, Karlin KD. Nitric oxide in biological denitrification: Fe/Cu metalloenzyme and metal complex NO(x) redox chemistry. Chem. Rev. 102, 1201-1234 (2002).
103. Jones KL, Hegab AH, Hillman F et al. Elevation of nitrotyrosine and nitrate concentrations in cystic fibrosis sputum. Pediatr. Pulmonol. 30, 79-85 (2000).
104. Rosenfeld M, Gibson RL, McNamara S et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonol. 32, 356-66 (2001).
105. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151, 1075-1082 (1995).
106. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Ped. Pulmonol. 20, 63-70 (1995).
107. Zahm JM, Gaillard D, Dupuit F et al. Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice. Am. J. Physiol. 272, C853-C859 (1997).
108. Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 165, 911-915 (2002).
109. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JM, Berger P. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am. J. Respir. Cell. Mol. Biol. 13, 257-261 (1995).
110. Chmiel JF, Konstan MW, Knesebeck JE et al. IL-10 attenuates excessive inflammation in chronic pseudomonas infection in mice. Am. J. Respir. Crit. Care Med. 160, 2040-2047 (1999).
111. Egan ME, Pearson M, Weiner SA et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304, 600-602 (2004).
112. Snouwaert JN, Brigman KK, Latour AM et al. An animal model for cystic fibrosis made by gene targeting. Science 257, 1083-1088 (1992).
113. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266, 1705-1708 (1994).
114. + absorption produces cystic fibrosis-like lung disease in mice. Nature Med. 10, 487-493 (2004).
115. Boucher, RC. Status of gene therapy for cystic fibrosis lung disease. J. Clin. Invest. 103, 441-445 (1999).
116. DeVries CA, Ohman DE. Mucoid-to-nonmucoid conversion in alginate-producing Pseudomonas aeruginosa often results from spontaneous mutations in algT, encoding a putative alternate σ-factor, and shows evidence for autoregulation. J. Bacteriol. 176, 6677-6687 (1994).